SEC Filings

Form 10-Q
VOYAGER THERAPEUTICS, INC. filed this Form 10-Q on 05/07/2019
Document Outline
Entire Document (5556.7 KB)
Subdocument 1 - 10-Q - 10-Q
Page 1 - UNITED STATES
Page 2 - Forward-Looking Statements
Page 3 - N/A
Page 4 - VOYAGER THERAPEUTICS, INC.
Page 5 - PART I. FINANCIAL INFORMATION
Page 6 - Voyager Therapeutics, Inc.
Page 7 - Voyager Therapeutics, Inc.
Page 8 - Voyager Therapeutics, Inc.
Page 9 - VOYAGER THERAPEUTICS INC.
Page 10 - 2. Summary of significant accounting policies and basis of presentation
Page 11 - Revenue recognition
Page 12 - Stock based compensation expense
Page 13 - Recently Adopted Accounting Pronouncements
Page 14 - 3. Fair value measurements
Page 15 - N/A
Page 16 - 5. Accrued expenses
Page 17 - 7. Commitments and contingencies
Page 18 - N/A
Page 19 - Accounting Analysis
Page 20 - AbbVie Tau Collaboration Agreement
Page 21 - N/A
Page 22 - Accounting Analysis
Page 23 - AbbVie Alpha Synuclein Collaboration Agreement
Page 24 - Accounting Analysis
Page 25 - N/A
Page 26 - Neurocrine Collaboration Agreement
Page 27 - N/A
Page 28 - Accounting Analysis
Page 29 - MRI Interventions Manufacturing and Supply Agreements
Page 30 - Other Agreements
Page 31 - 9. Stock based compensation
Page 32 - 2015 Employee Stock Purchase Plan
Page 33 - Restricted Stock Units
Page 34 - 10. Income taxes
Page 35 - ITEM 2. MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Page 36 - N/A
Page 37 - Recent results from PD-1102
Page 38 - Preclinical Pipeline Programs
Page 39 - in vivo
Page 40 - Financial Operations Overview
Page 41 - Commitments and Contingencies
Page 42 - General and Administrative Expenses
Page 43 - Compensation-Stock Compensation: Improvements to Nonemployee Share-Based Payment Accounting
Page 44 - Research and Development Expense
Page 45 - Liquidity and Capital Resources
Page 46 - Net Cash Provided by Financing Activities
Page 47 - AbbVie Alpha-Synuclein Collaboration
Page 48 - Neurocrine Collaboration
Page 49 - Contractual Obligations
Page 50 - ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Page 51 - Changes in Internal Control over Financial Reporting
Page 52 - N/A
Page 53 - We may not be able to generate sufficient revenue from the commercialization of our product candidat
Page 54 - We will need to raise additional funding, which may not be available on acceptable terms, or at all.
Page 55 - N/A
Page 56 - Raising additional capital may cause dilution to our stockholders, restrict our operations or requir
Page 57 - Risks Related to the Development and Regulatory Approval of Our Product Candidates
Page 58 - Results from preclinical studies and early stage clinical trials may not be indicative of efficacy i
Page 59 - The dosing and coverage of the putamen in the VY-AADC Phase 1b clinical trial, separate Phase 1 clin
Page 60 - N/A
Page 61 - We intend to conduct, and may in the future conduct, clinical trials for product candidates at sites
Page 62 - N/A
Page 63 - N/A
Page 64 - N/A
Page 65 - Our product candidates or the process for administering our product candidates may cause undesirable
Page 66 - We may be unable to obtain orphan drug designation or exclusivity for any of our product candidates
Page 67 - N/A
Page 68 - A potential breakthrough therapy designation by the FDA for our product candidates may not lead to a
Page 69 - Fast track designation by the FDA may not actually lead to a faster development or regulatory review
Page 70 - Even if we obtain regulatory approval for a product candidate, our products will remain subject to r
Page 71 - We face significant competition in an environment of rapid technological change and the possibility
Page 72 - N/A
Page 73 - Even if we obtain and maintain approval for our product candidates from the FDA, we may never obtain
Page 74 - Risks Related to Third Parties
Page 75 - N/A
Page 76 - N/A
Page 77 - We have only used the ClearPoint System to deliver our product candidates. While other devices for d
Page 78 - We may seek to enter into collaborations in the future with other third parties. If we are unable to
Page 79 - N/A
Page 80 - We have relied, and we expect to continue to rely, on third parties to conduct, supervise and monito
Page 81 - Risks Related to Manufacturing
Page 82 - Delays in obtaining regulatory approval of our or our collaborators manufacturing process and facili
Page 83 - Any contamination in the manufacturing process for our products or product candidates, shortages of
Page 84 - Our future success depends on our ability to retain key members of our management team, and to attra
Page 85 - Our employees, principal investigators, consultants and commercial partners may engage in misconduct
Page 86 - N/A
Page 87 - N/A
Page 88 - Under the Cures Act and the Trump Administration s regulatory reform initiatives, the FDA s policies
Page 89 - We may be subject, directly or indirectly, to federal, state, and foreign healthcare laws and regula
Page 90 - Product liability lawsuits against us could cause us to incur substantial liabilities and could limi
Page 91 - If we, our collaborators, or any third-party manufacturers engaged by us or our collaborators fail t
Page 92 - Unfavorable global economic conditions could adversely affect our business, financial condition or r
Page 93 - We might not be able to utilize a significant portion of our net operating loss carryforwards.
Page 94 - N/A
Page 95 - The insurance coverage and reimbursement status of newly approved products is uncertain. Failure to
Page 96 - N/A
Page 97 - The commercial success of any of our product candidates will depend upon its degree of market accept
Page 98 - Our gene therapy approach utilizes vectors derived from viruses, which may be perceived as unsafe or
Page 99 - Risks Related to Our Intellectual Property
Page 100 - N/A
Page 101 - If we are unable to obtain and maintain patent protection for our products and technology, or if the
Page 102 - Our intellectual property licenses with third parties may be subject to disagreements over contract
Page 103 - We may not be able to protect our intellectual property rights throughout the world.
Page 104 - Issued patents covering our technology or product candidates could be found invalid or unenforceable
Page 105 - Intellectual property litigation could cause us to spend substantial resources and distract our pers
Page 106 - Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our abi
Page 107 - If we do not obtain patent term extension and data exclusivity for our product candidates, our busin
Page 108 - Intellectual property rights do not necessarily address all potential threats.
Page 109 - Our reliance on third parties requires us to share our trade secrets, which increases the possibilit
Page 110 - Sales of a substantial number of shares of our common stock in the public market could cause our sto
Page 111 - We have broad discretion in how we apply our available funds, and we may not use these funds effecti
Page 112 - We are an emerging growth company and a smaller reporting company and the reduced disclosure require
Page 113 - Provisions in our amended and restated certificate of incorporation and bylaws and Delaware law coul
Page 114 - Our amended and restated certificate of incorporation designates the Court of Chancery of the State
Page 115 - INDEX TO EXHIBITS
Page 116 - SIGNATURES
Subdocument 2 - EX-10.5 - EX-10.5
Page 1 - Exhibit 10.5
Page 2 - Equity
Page 3 - 4. Certain Definitions
Page 4 - Good Reason
Page 5 - Sale Event Period
Page 6 - provided, howeverprovided further
Page 7 - 8. Payment in the Event of Revocation of Employment Offer Prior to Commencement Date Due to a Sale E
Page 8 - 10. Additional Limitation.
Page 9 - 12. Taxes
Page 10 - Date of Termination
Page 11 - 17. Governing Law; Consent to Jurisdiction; Forum Selection
Page 12 - 21. Notices
Page 13 - N/A
Page 14 - EXHIBIT A
Page 15 - VOYAGER THERAPEUTICS, INC.
Page 16 - 5. Developments.
Page 17 - Documents and Other Materials
Page 18 - 11. Prior Agreements.
Page 19 - 17. Exit Interview.
Page 20 - 23. Acknowledgements.
Page 21 - VOYAGER THERAPEUTICS, INC.
Page 22 - EXHIBIT A
Subdocument 3 - EX-31.1 - EX-31.1
Page 1 - N/A
Subdocument 4 - EX-31.2 - EX-31.2
Page 1 - N/A
Subdocument 5 - EX-32.1 - EX-32.1
Page 1 - N/A
XBRL Item - EX-101.INS - EX-101.INS (What's this?)
XBRL Item - EX-101.SCH - EX-101.SCH (What's this?)
XBRL Item - EX-101.CAL - EX-101.CAL (What's this?)
XBRL Item - EX-101.DEF - EX-101.DEF (What's this?)
XBRL Item - EX-101.LAB - EX-101.LAB (What's this?)
XBRL Item - EX-101.PRE - EX-101.PRE (What's this?)
XBRL Viewer